Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HARMONYL vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Harmonyl is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension (FDA-approved),Off-label: Management of opioid withdrawal symptoms, treatment of attention deficit hyperactivity disorder (ADHD), and reduction of menopausal hot flashes
Hypertension
25 mg orally once daily, taken with food. Maximum dose: 50 mg once daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal half-life: 12–18 hours (mean 15 h); extends to 24–30 h in hepatic impairment
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Hepatic metabolism via glucuronidation and sulfation; CYP450 enzymes not significantly involved.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal: 70% as unchanged drug; Biliary/fecal: 20% as metabolites; 10% other
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
95% bound primarily to albumin and alpha-1-acid glycoprotein
~90%, primarily to albumin
1.2–1.8 L/kg (mean 1.5 L/kg); indicates extensive tissue distribution
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 75%; IM: 90%
Oral: 50–60% (extensive first-pass metabolism)
GFR ≥ 30 m L/min: no adjustment. GFR 15-29 m L/min: reduce to 12.5 mg once daily. GFR < 15 m L/min: not recommended.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 12.5 mg once daily. Child-Pugh C: contraindicated.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Weight < 30 kg: not established. Weight ≥ 30 kg: 0.5 mg/kg orally once daily, up to 25 mg maximum.
Not recommended for pediatric use; safety in children under 12 years not established.
Initiate at 12.5 mg once daily; increase cautiously to 25 mg once daily based on tolerability and renal function.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
Abrupt discontinuation may cause rapid rise in blood pressure (rebound hypertension) and symptoms of sympathetic overactivity (e.g., nervousness, agitation, headache). This is particularly dangerous in patients on high doses or concurrent beta-blocker therapy.
None
Rebound hypertension upon abrupt withdrawal; caution in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, or chronic renal failure; may cause sedation and dry mouth; use caution in patients with history of depression.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to clonidine or any component; use with MAO inhibitors (hypertensive crisis risk); noncompliant patients who may abruptly discontinue therapy (risk of rebound hypertension).
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid tyramine-rich foods (e.g., aged cheeses, cured meats, fermented products) due to risk of hypertensive crisis. Limit alcohol intake as it may enhance orthostatic hypotension.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
FDA Pregnancy Category D. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and cleft palate due to folate antagonism. Second and third trimesters: risk of oligohydramnios, fetal renal dysfunction, and premature closure of ductus arteriosus if used after 30 weeks gestation.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Contraindicated during breastfeeding. M/P ratio: not determined. Excreted in human milk in low concentrations, but potential for serious adverse reactions in nursing infants, including hemolytic anemia and kernicterus due to sulfonamide component.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No established safe dose. Drug should be avoided during pregnancy. If unavoidable, use lowest effective dose for shortest duration. Trimethoprim component may require dose reduction due to increased glomerular filtration rate in pregnancy, but specific adjustment not validated. Sulfamethoxazole dose unchanged.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Harmonyl is a brand name for deserpidine, a Rauwolfia alkaloid used as an antihypertensive. It depletes catecholamines and serotonin from central and peripheral nerve endings. Onset of action is 1-2 weeks. Avoid in patients with history of depression, peptic ulcer, or pheochromocytoma. Monitor for bradycardia and hypotension. May cause extrapyramidal symptoms. Use with caution with MAOIs; avoid concurrent use.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take this medication exactly as prescribed, usually once daily.,Do not stop taking this medication abruptly; sudden withdrawal can cause severe hypertension.,You may experience dizziness or drowsiness; avoid driving or operating machinery until you know how the medication affects you.,Avoid alcohol while taking this medication.,Report any signs of depression, unusual mood changes, or difficulty sleeping to your doctor.,If you have a history of stomach ulcers, inform your doctor before starting this medication.,Keep all appointments for blood pressure monitoring.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HARMONYL vs ALDORIL 15, answered by our medical review team.
HARMONYL is a Antihypertensive that works by Harmonyl is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HARMONYL and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HARMONYL is: 25 mg orally once daily, taken with food. Maximum dose: 50 mg once daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HARMONYL and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HARMONYL is classified as Category C. FDA Pregnancy Category D. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and cleft palate due to folate antagonism. Second and third trimesters: . ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.